Crucell N.V.
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
25 nov 2008 - 08:44
Statutory name
Crucell N.V.
Title
DSM Biologics and Crucell Announce Commercial PER.C6® Licensing Agreement with Gedeon Richter
Comments
Leiden, The Netherlands/Parsippany, USA, 25 November 2008 – DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that Hungary-based Gedeon Richter Plc. signed a commercial license agreement allowing Gedeon Richter to develop and produce certain biopharmaceuticals on the PER.C6® platform. Other terms of the agreement were not disclosed.
About PER.C6® technology
Crucell's PER.C6® technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6® technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.
Date last update: 16 August 2025